Wang Y M, Cao B
Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Diseases, Department of Respiratory Medicine, Capital Medical University, Beijing 100029, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Aug 10;39(8):1051-1059. doi: 10.3760/cma.j.issn.0254-6450.2018.08.008.
Antiviral drugs on influenza are important in the control program of influenza. Options for influenza treatment are currently limited to using the neuraminidase inhibitors (NAIs). Given limited effectiveness of NAIs and related resistance, there remains an urgent need for the development of influenza antiviral drugs that can improve the efficacy and provide low propensity of viral resistance. Several influenza-related antiviral drugs that are currently under the late-stage clinical trials all appear differently in the mechanism of action. It is hoped that when new antiviral drugs are licensed, care and outcomes of severe influenza cases will be improved.
抗流感病毒药物在流感防控计划中至关重要。目前，流感治疗的选择仅限于使用神经氨酸酶抑制剂（NAIs）。鉴于NAIs的有效性有限以及相关耐药性问题，迫切需要研发能提高疗效且病毒耐药倾向低的抗流感病毒药物。目前处于后期临床试验阶段的几种与流感相关的抗病毒药物在作用机制上均有所不同。希望新的抗病毒药物获批后，重症流感病例的治疗护理及治疗效果能得到改善。
